Evidence map›Paper›PMID 40838051›Full record

ArticleFrontiers in drug delivery2023

Biodistribution of the saponin-based adjuvant Matrix-M™ following intramuscular injection in mice.

Cecilia Carnrot, Berit Carow, Anna-Karin E Palm, Eray Akpinar, Per-Henrik Helgesson, Ingrid Lekberg Osterman, Emelie Bringeland, Bryant Foreman, Nita Patel, Johan Bankefors and 2 more

Abstract read
In one paragraph

Article in Frontiers in drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Leaf Saponins ofPharmaceutics · 2025
    Review
  7. Article
  8. Review
  9. Intranasal Delivery ofVaccines · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Cecilia Carnrot *Adjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.
Berit Carow *Adjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.
Anna-Karin E Palm *Adjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.
Eray AkpinarAdjuvant Characterization, Product Development, Novavax AB, Uppsala, Sweden.
Per-Henrik HelgessonProduct Design and Formulation, Product Development, Novavax AB, Uppsala, Sweden.
Ingrid Lekberg OstermanAdjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.
Emelie BringelandAdjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.
Bryant ForemanVaccine Immunology, Novavax Inc., Gaithersburg, MD, United States.
Nita PatelVaccine Immunology, Novavax Inc., Gaithersburg, MD, United States.
Johan BankeforsAdjuvant Characterization, Product Development, Novavax AB, Uppsala, Sweden.
Louis FriesResearch and Development, Novavax Inc., Gaithersburg, MD, United States.
Linda StertmanAdjuvant Immunology, Product Development, Novavax AB, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel adjuvants are extensively utilized in the development of safe and effective vaccines against emerging pathogens. Matrix-M™ adjuvant is a saponin-based adjuvant used in several active clinical development programs and in widespread use in the COVID-19 vaccine NVX-CoV2373. Here, we conducted a biodistribution study to better understand the mechanism of action and safety profile for Matrix-M™ adjuvant. Radiolabeled saponins or cholesterol were incorporated into Matrix-A™ particles, which represent 85% of Matrix-M™. Labeled Matrix-M™ adjuvant was given to mice by intramuscular injection with or without SARS-CoV-2 Spike protein. Radioactivity of the adjuvant components was quantified in local and systemic tissues at seven timepoints over a period of 1-168 h. The highest saponin levels were found at the 1-h timepoint at the injection site, in the draining (iliac) lymph nodes, and in urine. Saponins were rapidly cleared from these tissues, reaching very low levels by 48-72 h. Systemically, saponins were found at low levels in the plasma, kidneys, liver, and bone marrow, and were barely detectable in other investigated tissues. Cholesterol was also found at high levels at the injection site and in the draining lymph nodes. These levels declined rapidly at first, then plateaued at 24-48 h. Radiolabeled cholesterol was found at very low levels in other tissues at the earliest timepoints, until increasing and stabilizing after the 24-h timepoint, indicating entry into the endogenous cholesterol recycling pool. This study demonstrates a rapid distribution of Matrix-M™ adjuvant from the injection site to the draining lymph nodes, thus excluding a depot effect as central to the mechanism of action for this adjuvant. The diverging clearance patterns for saponins and cholesterol are suggestive of at least partial disassembly of the Matrix-particles, which has implications for the downstream effects of Matrix-M™ adjuvant on adaptive immune responses. Systemic exposure to toxicologically relevant tissues is very low.

Indexed as

COVID-19draining lymph nodemechanism of actionNVX-CoV2373vaccinevaccine safety

Identifiers

PMID40838051
PMCPMC12363263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.